How IV Ketamine Works for Depression: Glutamate, Neuroplasticity, and mTOR

SSRIs and other traditional antidepressants work by increasing the availability of serotonin at brain synapses, a process that takes weeks to translate into a noticeable mood change. Ketamine’s effects, when they occur, often show up within hours to a day [Murrough 2013] — a difference in timeline so large that it pointed researchers toward a completely different mechanism. That mechanism centers on glutamate rather than serotonin.

Ketamine blocks NMDA receptors, one of the brain’s main receptors for glutamate. Counterintuitively, blocking this receptor appears to trigger a brief surge of glutamate release elsewhere in the circuit, which activates a different type of glutamate receptor — the AMPA receptor. This AMPA receptor activation is thought to be a key step connecting ketamine’s immediate pharmacological action to its downstream antidepressant effects. [Zanos & Gould 2018]

Downstream of that AMPA receptor activation, ketamine rapidly activates a cellular signaling pathway called mTOR (mammalian target of rapamycin). In an influential 2010 study, researchers found that ketamine administration in rats activated mTOR signaling and led to a measurable increase in the number and function of synapses — the connections between neurons — in the prefrontal cortex, within hours. [Li 2010] Blocking mTOR signaling in the same study eliminated both the synaptic growth and the antidepressant-like behavioral effect, tying the two together directly.

This matters because chronic stress and depression are associated with the opposite pattern — a loss of synaptic connections in the prefrontal cortex. The leading model suggests ketamine’s antidepressant effect works, at least in part, by rapidly reversing that loss.

This specific study was conducted in an animal model, not in humans. It is the foundational evidence for the mTOR and synaptogenesis pathway, and much of what is understood about ketamine’s mechanism traces back to animal research like this — but it is a meaningful scientific distinction we want to be upfront about, not something to gloss over.

A related line of research points to brain-derived neurotrophic factor (BDNF), a protein involved in the growth and maintenance of neurons. In an animal model, a rapid antidepressant-like response to NMDA receptor blockade depended on BDNF being released and available at the synapse — when BDNF release was blocked, so was the behavioral antidepressant effect. [Autry 2011] BDNF is thought to work alongside the mTOR pathway to support the new synaptic connections described above.

This mechanism offers a plausible explanation for several things observed clinically:

• why effects can appear within hours rather than weeks;
• why a single infusion's benefit is often temporary — the synaptic changes appear to be time-limited without reinforcement;
• why a multi-infusion induction series — covered in our dosing and induction guide — may help sustain the response rather than a single dose alone.

What it does not yet fully explain is the complete picture. Ketamine’s antidepressant mechanism is an active area of research, and several other pathways are being studied alongside the glutamate and mTOR model, including effects on inhibitory GABA-releasing neurons and on a brain region called the lateral habenula that is linked to negative mood states. [Zanos & Gould 2018] The honest scientific answer, as of this writing, is that the glutamate and mTOR pathway is the best-supported and most widely cited explanation — not a completely closed case.

The clearest thing the science can say is that ketamine is not a faster serotonin drug. It works through glutamate, and the leading model ties its rapid effect to new synaptic connections built through the mTOR pathway. That model rests heavily on animal research, and researchers describe it as leading, not settled.

For patients, the practical takeaway is why treatment is structured the way it is: the effect can be fast, it tends to fade without reinforcement, and that is the reason induction is a series rather than a single dose.